FierceBiotechOriginal article
{"a":[{"_":"Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod","$":{"href":"/biotech/leo-bets-435m-tanabes-regulatory-approval-ready-rare-dermatology-drug","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Leo Pharma acquired a rare skin disease drug from Tanabe Pharma for $435 million. The drug is currently awaiting an FDA approval decision.
Outcome Details
FDA approval decision pending
Importance:7/10
Sentiment:
0.60
M&Arare diseasedermatologyFDA approval pending
Read the original article
Published by FierceBiotech on August 17, 2026 8:24 AM